The REMS Report Card: FDA Using New Tools For One-Third Of New Drugs In First Six Months
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
FDA has used its new authority to impose a Risk Evaluation and Mitigation Strategy on roughly one-third of all new molecular entities approved since the REMS provisions of the FDA Amendments Act took effect at the end of March.
You may also be interested in...
Cymbalta Pregnancy Risk Fit FDA's New Power To Mandate Post-Market Study
FDA's application of its new ability to require - as opposed to request - post-marketing studies under the FDA Amendments Act is on display in the review of a fibromyalgia claim for Lilly's Cymbalta (duloxetine)
Cymbalta Pregnancy Risk Fit FDA's New Power To Mandate Post-Market Study
FDA's application of its new ability to require - as opposed to request - post-marketing studies under the FDA Amendments Act is on display in the review of a fibromyalgia claim for Lilly's Cymbalta (duloxetine)
Drug Safety’s “Equal Voice” To Be Considered At Internal CDER Workshop
Review staff from the Center for Drug Evaluation and Research will meet in December to discuss how to implement the concept of giving an "equal voice" to safety personnel during regulatory decision-making